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Introduction {#cam41186-sec-0001}
============

Prostate cancer is the most common male cancer in westernized countries with an estimated 1.1 million men diagnosed with prostate cancer in 2012 worldwide [1](#cam41186-bib-0001){ref-type="ref"}. In France, more than 50,000 cases of prostate cancer were diagnosed in 2011, with almost 9000 related deaths that same year making it the third cause of cancer‐related mortality [2](#cam41186-bib-0002){ref-type="ref"}.

Except age, ethnic origin, and family history of prostate cancer that are well‐established nonmodifiable risk factors, the etiology of prostate cancer remains largely unknown. Accumulating epidemiological, biological, genetic, and experimental evidence suggested that chronic inflammation may be associated either with initiation or progression of several cancers, including prostate cancer [3](#cam41186-bib-0003){ref-type="ref"}, [4](#cam41186-bib-0004){ref-type="ref"}, [5](#cam41186-bib-0005){ref-type="ref"}, [6](#cam41186-bib-0006){ref-type="ref"}. Indeed, inflammatory cells as well as the chemokines and cytokines they produce confer a microenvironment favorable to tumor growth, by increasing the production of reactive oxygen species leading to oxidative DNA damage and reduce DNA repair, and tumor progression by promoting angiogenesis [3](#cam41186-bib-0003){ref-type="ref"}, [4](#cam41186-bib-0004){ref-type="ref"}, [5](#cam41186-bib-0005){ref-type="ref"}.

Regarding prostate cancer, the presence of inflammatory infiltrations localized near zones of proliferative inflammatory atrophy and prostatic intraepithelial neoplasia, considered to be potentially precancerous prostatic lesions, has contributed to reinforce the hypothesis of a possible link between chronic inflammation and prostate cancer [7](#cam41186-bib-0007){ref-type="ref"}. Moreover, prostate tissues with histological evidence of inflammation were more likely to develop prostate cancer than those without inflammation [8](#cam41186-bib-0008){ref-type="ref"}. The mechanism of inflammation is based on the action of the cyclooxygenase (COX), enzyme that catalyzes messenger molecules in inflammation pathways [9](#cam41186-bib-0009){ref-type="ref"}. There are two distinct isoforms of the COX enzyme: COX‐1, constitutively expressed in most tissues and involved in physiological functions, and COX‐2, expressed in several tissues during inflammation. Indeed, an overexpression of COX‐2 in human prostate cancer tissue compared to benign prostate tissue has been reported [10](#cam41186-bib-0010){ref-type="ref"}. Therefore, nonsteroidal anti‐inflammatory drugs (NSAIDs), used for their analgesic and antipyretic properties, and at higher doses, for their anti‐inflammatory effects, have received attention for their potential as chemopreventive drugs against cancer. They may be characterized according to their ability to preferentially inhibit COX‐1 as aspirin or COX‐2 as coxibs or oxicams [11](#cam41186-bib-0011){ref-type="ref"}.

Most epidemiological studies reported an inverse association between aspirin and cancer risk, especially for colorectal cancer [12](#cam41186-bib-0012){ref-type="ref"}. Modest inverse associations were also reported with aspirin use and prostate cancer occurrence in observational studies or meta‐analysis [13](#cam41186-bib-0013){ref-type="ref"}, [14](#cam41186-bib-0014){ref-type="ref"}, [15](#cam41186-bib-0015){ref-type="ref"}, [16](#cam41186-bib-0016){ref-type="ref"}, [17](#cam41186-bib-0017){ref-type="ref"}. Evidence for nonaspirin NSAIDs (NA‐NSAID) use and inverse association with cancer are even more scarce, with at least three observational studies showing even a positive association with prostate cancer risk [18](#cam41186-bib-0018){ref-type="ref"}, [19](#cam41186-bib-0019){ref-type="ref"}, [20](#cam41186-bib-0020){ref-type="ref"} and others showing null or weak negative association [21](#cam41186-bib-0021){ref-type="ref"}, [22](#cam41186-bib-0022){ref-type="ref"}, [23](#cam41186-bib-0023){ref-type="ref"}, [24](#cam41186-bib-0024){ref-type="ref"}, [25](#cam41186-bib-0025){ref-type="ref"}, [26](#cam41186-bib-0026){ref-type="ref"}, [27](#cam41186-bib-0027){ref-type="ref"}, [28](#cam41186-bib-0028){ref-type="ref"}. Meta‐analysis could not give strong conclusions because of striking heterogeneity between studies [14](#cam41186-bib-0014){ref-type="ref"}, [15](#cam41186-bib-0015){ref-type="ref"}, [16](#cam41186-bib-0016){ref-type="ref"}, [29](#cam41186-bib-0029){ref-type="ref"}, with only one showing modest inverse association [16](#cam41186-bib-0016){ref-type="ref"} and three of them null association.

Few of these studies provided data on type of NSAIDs and anti‐COX preferential activity, frequency, duration, recency of use, circumstances of prescription, and addressed the aggressiveness of cancer.

In this context, our main objective was to study the association between NSAIDs use (aspirin and nonaspirin NSAIDs) and prostate cancer risk based on the data from the EPICAP study.

Materials and Methods {#cam41186-sec-0002}
=====================

Study population {#cam41186-sec-0003}
----------------

EPICAP (EPIdemiology of Prostate CAncer) is a population‐based case--control study which details of the study protocol have been published elsewhere [30](#cam41186-bib-0030){ref-type="ref"}. Cases were men newly diagnosed with histologically confirmed prostate cancer between 2012 and 2013, aged less than 75 years old, and living in the *département* of Hérault, France at the time of diagnosis. The identification of the cases was realized by clinical research nurses, specifically trained for the study, by active search in all public and private cancer care centers of the *département*. Only cases who gave their informed consent were included in the study. Controls were men randomly selected in the general population, frequency matched to the cases, living in the *département* of Hérault as the cases, and with no history of prostate cancer at the time of inclusion. Quotas by age were established as a preliminary to yield the control group similar to the case group in terms of age in order to achieve frequency matching (5 year age group). Quotas by socioeconomic status (SES) were also set a priori to control for potential selection bias arising from differential participation rates across SES categories. These quotas by SES were calculated from the census data available in the *département* of Hérault, in order to obtain a distribution by SES among controls identical to the SES distribution among general male population, conditionally to age.

A total of 1098 cases and 1109 controls were eligible, of which 819 and 879, respectively, were included in the study representing a participation rate of 75% for cases and 79% for controls.

Data collection {#cam41186-sec-0004}
---------------

Trained clinical research nurses conducted face to face interviews of cases and controls using a standardized questionnaire based on a CAPI system (Computer‐Assisted Personal Interview). Detailed information on socioeconomic characteristics, personal medical history and drugs use, family history of cancer, diet, tobacco, and alcohol consumption, physical activity, and residential and occupational history were gathered.

Cases and controls were asked about their lifetime aspirin and NA‐NSAIDs consumption, and more specifically about the name, the frequency, and the duration of the specific NSAID they used. They were also asked about the reason of NSAID use and if the use was under medical prescription or over the counter.

For prostate cancer cases, medical information such as Gleason score or PSA at diagnosis had been extracted from their medical record or from the Hérault Cancer Registry.

Statistical analysis {#cam41186-sec-0005}
--------------------

All analyses were performed using SAS 9.4 software (SAS Institute Inc., Cary, NC). NSAIDs were divided into three categories: overall users (all‐NSAIDs), aspirin users (aspirin), and nonaspirin NSAID users (NA‐NSAIDs). All‐NSAIDs users were defined as users of aspirin or NA‐NSAIDs at least once a month. Men who never took, or less than once a month, any kind of NSAIDs were considered as nonusers (reference class). The frequency of use (\<1/day, =1/day, ≥1/day), duration of use (\<5 years, 5--10 years, \>10 years), and recency of use (former, current) were analyzed for all‐NSAIDs, aspirin, and NA‐NSAIDs users. We also classified NSAIDs according to their anti‐COX‐1 or anti‐COX‐2 preferential activity based on the known COX‐1/COX‐2 ratio of each NSAID. Coxib, diclofenac, etodolac, and oxicams inhibit preferentially COX‐2 (ratio \<1), while aspirin, propionates, and indometacin inhibit preferentially COX‐1 [11](#cam41186-bib-0011){ref-type="ref"}.

Unconditional logistic regression models were used to estimate odds ratios (ORs) and their 95% confidence intervals (CIs). Analyses were systematically adjusted for age (5‐year period), family history of prostate cancer in first‐degree relatives and race (Caucasians, others). Analyses were also adjusted for other potential confounding factors such as educational level, body mass index (BMI) (\<25/25--30/≥30) or waist to hip ratio (WHR) (\<0.95/≥0.95), and personal prostatitis history (no: no personal history of prostatitis/yes: at least one personal history of acute or chronic prostatitis).

Separate analyses were also conducted by prostate cancer aggressiveness according to the Gleason score (low or intermediate score ≤7 \[including 3 + 4\], high score ≥7 \[including 4 + 3\]).

Ethics statement {#cam41186-sec-0006}
----------------

Each subject enrolled in the study provides their written informed consent. The EPICAP study was approved by the Institutional Review Board of the French National Institute of Health and Medical Research (IRB‐Inserm No. 01‐040, November 2010) and by the French data Protection Authority (CNIL No. 910485, April 2011).

Results {#cam41186-sec-0007}
=======

The characteristics of prostate cancer cases and controls are presented in Table [1](#cam41186-tbl-0001){ref-type="table-wrap"}. We enrolled 819 prostate cancer cases and 879 population‐based controls, and among them, age distribution in 5‐year groups was the same in both cases and controls (*P* = 0.19). Among cases of prostate cancer, 76% had a low or intermediate Gleason score ≤7 (including 3 + 4), and 22% had a high score ≥7 (including 4 + 3), that is, aggressive cancer, and among them, 10% had a Gleason score over 7. Our study population was predominantly Caucasian (\>95% for both cases and controls). Family history of prostate cancer in first‐degree relatives was more frequent in cases than in controls (22% in cases vs. 9% in controls, *P* \< 0.0001), consistent with the literature. Considering anthropomorphic data, BMI was similar in cases and controls (*P* = 0.79), while WHR was significantly higher in cases than in controls (73% of cases vs. 67% of controls, *P* = 0.03). Personal history of certain comorbidities, such as cardiovascular background (myocardial infarction, hypertension, stroke, diabetes) and rheumatologic background, were similarly distributed between cases and controls (*P* = 0.56, *P* = 0.52, respectively), while personal history of prostatitis was significantly more frequent in cases than in controls (*P* = 0.02).

###### 

Study population characteristics

                                                                     Cases *n* = 819 (%)   Controls *n* = 879 (%)   *P*‐value[a](#cam41186-note-0003){ref-type="fn"}
  ------------------------------------------------------------------ --------------------- ------------------------ --------------------------------------------------
  Gleason score                                                                                                     
  ≤7 (3 + 4)                                                         623 (76)              --                       
  ≥7 (4 + 3)                                                         180 (22)              --                       
  Age at diagnosis/interview, years                                  0.19                                           
  40--55                                                             48 (6)                59 (7)                   
  55--60                                                             99 (12)               99 (11)                  
  60--65                                                             217 (27)              201 (23)                 
  65--70                                                             274 (33)              285 (32)                 
  70--75                                                             181 (22)              235 (27)                 
  Race                                                               0.43                                           
  Caucasian                                                          795 (97)              859 (98)                 
  Other                                                              24 (3)                20 (2)                   
  Family history of prostate cancer at first degree                  \<0.0001                                       
  No                                                                 549 (67)              723 (82)                 
  Yes                                                                181 (22)              77 (9)                   
  Educational level                                                  0.22                                           
  No diploma                                                         70 (9)                72 (8)                   
  Up to high school                                                  376 (46)              436 (50)                 
  High school                                                        113 (14)              110 (13)                 
  College                                                            260 (32)              260 (30)                 
  Smoking status                                                     0.077                                          
  Never                                                              240 (29)              246 (28)                 
  Ex‐smoker                                                          455 (56)              476 (54)                 
  Smoker                                                             123 (15)              157 (18)                 
  Body mass index (BMI)                                              0.79                                           
  \<25                                                               231 (28)              248 (28)                 
  25--29                                                             399 (49)              397 (45)                 
  ≥30                                                                182 (22)              207 (24)                 
  Waist to hip ratio (WHR)                                           0.03                                           
  \<0.95                                                             214 (26)              265 (30)                 
  ≥0.95                                                              594 (73)              590 (67)                 
  Prostatitis history                                                0.02                                           
  No                                                                 735 (90)              816 (93)                 
  Yes                                                                84 (10)               63 (7)                   
  Cardiovascular background[b](#cam41186-note-0004){ref-type="fn"}   0.56                                           
  No                                                                 432 (53)              443 (51)                 
  Yes                                                                384 (47)              427 (49)                 
  Rheumatologic background[c](#cam41186-note-0005){ref-type="fn"}    0.52                                           
  No                                                                 626 (78)              662 (77)                 
  Yes                                                                175 (21)              202 (23)                 

Adjusted for age.

Myocardial infarction, hypertension, stroke, diabetes.

Rheumatoid polyarthritis, spondylarthropathies, arthrosis.

John Wiley & Sons, Ltd

Sociodemographic and lifestyle characteristics of all‐NSAID users and nonusers among controls are shown in Table [2](#cam41186-tbl-0002){ref-type="table-wrap"}. NSAIDs users and nonusers were similar in terms of age, family history of prostate cancer in first‐degree relatives, educational level, and smoking status (*P* = 0.23, *P* = 0.15, *P* = 0.31, *P* = 0.35, respectively). In the contrary, NSAIDs users were more likely to have a BMI of 30 and above, a personal history of prostatitis, a cardiovascular or a rheumatologic background than nonusers (*P* = 0.002, *P* = 0.002, *P* \< 0.0001, *P* \< 0.0001, respectively).

###### 

Characteristics of NSAIDs users and nonusers among controls

                                                                     All *n* = 879              
  ------------------------------------------------------------------ --------------- ---------- --
  Age at diagnosis/interview, years                                  0.10                       
  40--55                                                             42 (7)          13 (5)     
  55--60                                                             69 (12)         30 (11)    
  60--65                                                             141 (24)        58 (21)    
  65--70                                                             189 (32)        92 (34)    
  70--75                                                             152 (26)        79 (29)    
  Race                                                               0.06                       
  Caucasian                                                          583 (98)        262 (96)   
  Other                                                              10 (2)          10 (4)     
  Family history of prostate cancer at first degree                  0.05                       
  No                                                                 495 (83)        215 (79)   
  Yes                                                                45 (8)          32 (12)    
  Educational level                                                  0.28                       
  No diploma                                                         45 (8)          24 (9)     
  Up to high school                                                  295 (50)        134 (49)   
  High school                                                        69 (11)         39 (14)    
  College                                                            184 (31)        74 (27)    
  Smoking status                                                     0.58                       
  Never                                                              169 (29)        76 (28)    
  Ex‐smoker                                                          320 (54)        147 (54)   
  Smoker                                                             104 (18)        49 (18)    
  Body mass index (BMI)                                              0.002                      
  \<25                                                               177 (30)        67 (25)    
  25--29                                                             281 (47)        106 (39)   
  ≥30                                                                122 (21)        85 (31)    
  Waist to hip ratio (WHR)                                           0.67                       
  ≤95                                                                184 (30)        78 (29)    
  \>95                                                               396 (67)        183 (67)   
  Prostatitis history                                                0.002                      
  No                                                                 561 (95)        241 (89)   
  Yes                                                                32 (5)          31 (11)    
  Cardiovascular background[b](#cam41186-note-0007){ref-type="fn"}   \<0.0001                   
  No                                                                 333 (57)        103 (38)   
  Yes                                                                255 (43)        165 (61)   
  Rheumatologic background[c](#cam41186-note-0008){ref-type="fn"}    \<0.0001                   
  No                                                                 476 (81)        175 (64)   
  Yes                                                                111 (19)        88 (32)    

Adjusted for age.

Myocardial infarction, hypertension, stroke, diabetes.

Rheumatoid polyarthritis, spondylarthropathies, arthrosis.

John Wiley & Sons, Ltd

We observed that 220 (27%) cases and 272 (31%) controls had ever used all‐NSAIDs (OR 0.77, 95% CI 0.61--0.98) (Table [3](#cam41186-tbl-0003){ref-type="table-wrap"}). The association decreased with the frequency of use (OR 0.93, 95% CI 0.68--1.27 for less than 1 use per day; OR 0.75, 95% CI 0.54--1.04 for 1 use per day; OR 0.38, 95% CI 0.18--0.79 for more than 1 use per day; *P* trend = 0.003) and was more pronounced for a duration of 5--10 years (OR 0.55, 95% CI 0.33--0.92), for a current use (OR 0.68, 95% CI 0.50--0.94), and when the NSAIDs use had a preferentially anti‐COX‐2 activity (OR 0.48, 95% CI 0.28--0.79).

###### 

Associations between NSAIDs use and prostate cancer risk

                            Cases *n* = 819 (%)   Controls *n* = 879 (%)   OR (95% CI)[a](#cam41186-note-0012){ref-type="fn"}
  ------------------------- --------------------- ------------------------ ----------------------------------------------------
  All‐NSAIDs                                                               
  Nonuse                    596 (73)              593 (67)                 1.00
  Ever‐use                  220 (27)              272 (31)                 0.77 (0.61--0.98)
  Drug issuance                                                            
  Over the counter          34 (4)                33 (4)                   1.00 (0.57--1.75)
  Medical prescription      181 (22)              229 (26)                 0.76 (0.59--0.98)
  Anti‐COX activity                                                        
  Preferential anti‐COX‐1   160 (20)              186 (22)                 0.85 (0.65--1.11)
  Preferential anti‐COX‐2   32 (4)                57 (7)                   0.48 (0.28--0.79)
  Frequency                                                                
  \<1/day                   109 (13)              108 (12)                 0.93 (0.68--1.27)
  =1/day                    93 (11)               121 (14)                 0.75 (0.54--1.04)
  \>1/day                   11 (1)                30 (3)                   0.38 (0.18--0.79)
  Duration (years)                                                         
  \<5                       62 (8)                81 (9)                   0.67 (0.45--0.99)
  5--10                     33 (4)                53 (6)                   0.55 (0.33--0.92)
  \>10                      120 (15)              133 (15)                 0.94 (0.69--1.27)
  Recency                                                                  
  Former use                119 (15)              125 (14)                 0.87 (0.64--1.18)
  Current use               101 (12)              147 (17)                 0.68 (0.50--0.94)
  Current use ≤10 years     41 (5)                69 (8)                   0.55 (0.35--0.87)
  Current use \>10 years    58 (7)                78 (9)                   0.79 (0.52--1.20)
  Former use ≤10 years      54 (7)                65 (7)                   0.69 (0.45--1.06)
  Former use \>10 years     62 (8)                55 (6)                   1.11 (0.73--1.69)

Adjusted for age, family history of cancer at first degree, race, educational level, history of prostatitis, WHR.

John Wiley & Sons, Ltd

Associations for aspirin use and NA‐NSAIDs use are presented in Table [4](#cam41186-tbl-0004){ref-type="table-wrap"}. Aspirin use was slightly negatively, but not significantly, associated with prostate cancer (OR 0.86, 95% CI 0.65--1.14). Nevertheless, a frequency of 1 use per day, a duration of 5--10 years, and a current use were significantly negatively associated with prostate cancer (OR 0.59, 95% CI 0.39--0.89; OR 0.49, 95% CI 0.27--0.90; OR 0.70, 95% CI 0.48--1.00, respectively). NA‐NSAIDs use was also negatively associated with prostate cancer (OR 0.72, 95% CI 0.53--0.99), especially under medical prescription (OR 0.71, 95% CI 0.51--0.97). There was neither frequency nor duration clear effect, but current use was strongly negatively associated (OR 0.52, 95% CI 0.30--0.91).

###### 

Associations between aspirin, NA‐NSAIDs use, and prostate cancer risk

                           Aspirin    NA‐NSAIDs                                             
  ------------------------ ---------- ----------- ------------------- ---------- ---------- -------------------
  Nonuse                   596 (73)   593 (67)    1.00                596 (73)   593 (67)   1.00
  Ever‐use                 143 (17)   166 (19)    0.86 (0.65--1.14)   107 (13)   143 (16)   0.72 (0.53--0.99)
  Drug issuance                                                                             
  Over the counter         39 (5)     41 (5)      0.91 (0.54--1.53)   2 (0)      2 (0)      1.96 (0.17--22.7)
  Medical prescription     102 (12)   120 (14)    0.86 (0.62--1.19)   100 (12)   136 (15)   0.71 (0.51--0.97)
  Frequency                                                                                 
  \<1 /day                 83 (10)    58 (7)      1.39 (0.93--2.06)   49 (6)     72 (8)     0.70 (0.46--1.06)
  =1/day                   54 (7)     90 (10)     0.59 (0.39--0.89)   43 (5)     40 (5)     0.88 (0.53--1.45)
  \>1/day                  4 (0)      13 (1)      0.32 (0.10--1.03)   8 (1)      18 (2)     0.53 (0.22--1.30)
  Duration (years)                                                                          
  \<5                      33 (4)     43 (5)      0.66 (0.38--1.13)   38 (5)     56 (6)     0.70 (0.43--1.13)
  5--10                    23 (3)     41 (5)      0.49 (0.27--0.90)   16 (2)     19 (2)     0.88 (0.40--1.93)
  \>10                     85 (10)    81 (9)      1.14 (0.79--1.65)   49 (6)     64 (7)     0.70 (0.45--1.09)
  Recency                                                                                   
  Former use               66 (8)     59 (7)      1.11 (0.73--1.67)   81 (10)    94 (11)    0.82 (0.58--1.18)
  Current use              77 (9)     107 (12)    0.70 (0.48--1.00)   26 (3)     49 (6)     0.52 (0.30--0.91)
  Current use ≤10 years    32 (4)     55 (6)      0.54 (0.32--0.90)   10 (1)     21 (2)     0.41 (0.17--1.00)
  Current use \>10 years   43 (5)     52 (6)      0.85 (0.52--1.40)   16 (2)     28 (3)     0.61 (0.30--1.23)
  Former use ≤10 years     24 (3)     29 (3)      0.64 (0.34--1.22)   44 (5)     54 (6)     0.88 (0.55--1.41)
  Former use \>10 years    42 (5)     29 (3)      1.60 (0.94--2.71)   33 (4)     36 (4)     0.76 (0.44--1.31)

Adjusted for age, family history of cancer at first degree, race, educational level, history of prostatitis, WHR.

John Wiley & Sons, Ltd

We performed all analyses according to the aggressiveness of prostate cancer (Table [5](#cam41186-tbl-0005){ref-type="table-wrap"}). NA‐NSAIDs use was negatively associated with aggressive prostate cancer (OR 0.49, 95% CI 0.27--0.89 vs. OR 0.78, 95% CI 0.56--1.09 for low or intermediate score); especially NA‐NSAID with preferential anti‐COX‐2 activity (OR 0.33, 95% CI 0.11--0.94). This association was not found with aspirin use.

###### 

Associations between NSAIDs use and prostate cancer risk according to Gleason score

                                       Low‐ or intermediate‐grade prostate cancer Gleason score ≤7 (3 + 4)   High‐grade prostate cancer Gleason score ≥7 (4 + 3)              
  ------------------------- ---------- --------------------------------------------------------------------- ----------------------------------------------------- ---------- -------------------
  All‐NSAIDs                                                                                                                                                                  
  Nonuser                   593 (67)   446 (72)                                                              1.00                                                  140 (77)   1.00
  Ever‐user                 272 (31)   175 (28)                                                              0.82 (0.64--1.06)                                     42 (23)    0.62 (0.41--0.95)
  Preferential anti‐COX‐1   186 (21)   126 (20)                                                              0.88 (0.66--1.18)                                     33 (18)    0.77 (0.49--1.21)
  Preferential anti‐COX‐2   57 (6)     25 (4)                                                                0.48 (0.28--0.84)                                     5 (3)      0.33 (0.11--0.94)
  Aspirin                   166 (19)   113 (18)                                                              0.89 (0.66--1.21)                                     29 (16)    0.77 (0.48--1.24)
  NA‐NSAIDs                 143 (16)   86 (14)                                                               0.78 (0.56--1.09)                                     18 (10)    0.49 (0.27--0.89)

Adjusted for age, family history of cancer at first degree, race, educational level, history of prostatitis, WHR.

John Wiley & Sons, Ltd

Finally, stratifying on history of prostatitis (Table [6](#cam41186-tbl-0006){ref-type="table-wrap"}), the inverse association observed with NSAIDs was reinforced among patients with a personal history of prostatitis (OR 0.32, 95% CI 0.15--0.71) compared to men with no history of prostatitis (OR 0.85, 95% CI 0.67--1.09); especially among NA‐NSAID users (OR 0.21, 95% CI 0.07--0.59 vs. OR 0.82, 95% CI 0.59--1.12, respectively). Interaction was statistically significant for all‐NSAIDs use (*P* = 0.02).

###### 

Associations between NSAIDs use and prostate cancer risk according to personal history of prostatitis

               No history of prostatitis (*n* = 1551)   History of prostatitis (*n* = 147)                                           
  ------------ ---------------------------------------- ------------------------------------ ------------------- --------- --------- -------------------
  All‐NSAIDs                                                                                                                         
  Nonuser      534 (73)                                 561 (69)                             1.00                62 (74)   32 (51)   1.00
  Ever‐user    198 (27)                                 241 (30)                             0.85 (0.67--1.09)   22 (26)   31 (49)   0.32 (0.15--0.71)
  Aspirin      130 (18)                                 152 (19)                             0.91 (0.68--1.22)   13 (15)   14 (22)   0.43 (0.17--1.14)
  NA‐NSAIDS    96 (13)                                  123 (15)                             0.82 (0.59--1.12)   11 (13)   20 (32)   0.21 (0.07--0.59)

Adjusted for age, family history of cancer at first degree, race, educational level, WHR.

John Wiley & Sons, Ltd

All analyses were also adjusted for the reason of NSAIDs use such as cardiovascular and rheumatologic backgrounds, and results remained unchanged.

Discussion {#cam41186-sec-0008}
==========

This study showed that NSAIDs consumption was negatively associated with prostate cancer occurrence, with a 23% reduction in prostate cancer risk, with convincing inverse associations of both aspirin and NA‐NSAIDs use. This association was more pronounced with a frequency of one or more pill a day and a current and chronic duration for all‐NSAIDs users, reaching a 52% decreased risk for anti‐COX‐2 activity users.

Our results are based on a large carefully designed population‐based case--control study conducted specifically to assess environmental and genetic factors in prostate cancer risk. Cases were identified in all cancer hospitals, either public or private, that recruited prostate cancer patients in the *département* of Hérault. In 2012, the Hérault Cancer Registry observed 770 new cases of prostate cancer, of which 575 were under 75 years of age. Considering that the number of cases observed in 2011 was identical, approximately 1150 new cases were expected during the study period (2012--2013) [31](#cam41186-bib-0031){ref-type="ref"}. We identified 1098 eligible cases over the study period suggesting that the recruitment of cases in the EPICAP study was exhaustive, thus limiting a potential selection bias. Even though participation rate in cases was 75%, the age distribution and the Gleason score were comparable to those of the Hérault Cancer Registry for the years 2009--2011 (private communication), which indicates that cases included in the study were representative of all eligible cases. Controls were randomly selected from the general population of the *département* of Hérault using quotas on age (5 years) to reflect the age distribution of the cases. Moreover, quotas by socioeconomic status (SES) have been established to yield the control group similar to the general population of the *département* of Hérault of the same age in terms of SES. After the selection process, we compared the distribution by SES between our control group and the male general population of the *département* of Hérault and found no significant difference, indicating that no major selection bias by SES had occurred.

To minimize misclassification of exposure, data were collected by a trained research clinical nurse using a standardized questionnaire. Many details on former and current use of NSAIDs with exhaustive questions on name of the drug, indication, prescription by a doctor or over the counter, frequency, recency, and duration of use were collected. In our study, prevalence of exposure to all‐NSAIDs was 31% among controls which was similar to other studies using questionnaires [19](#cam41186-bib-0019){ref-type="ref"}, [27](#cam41186-bib-0027){ref-type="ref"}. Recall bias is often an issue in case--control studies. Nevertheless, the use of a standardized questionnaire, a face to face interview by a research clinical nurses, and the fact that cases and controls were interviewed under the same conditions minimize the possibility of such bias. Moreover, a recall bias is usually more frequent in cases than in controls which may explain a positive association but not an inverse association as we observed in our results.

Our results were unchanged after adjustment for potential major confounding factors such as family history of prostate cancer, anthropometric indicators, or reason for NSAIDs use (cardiovascular and rheumatologic backgrounds), limiting potential confounding.

Detection bias, meaning that patient under NSAIDs would have had more frequent contact with doctors and therefore more cancers detected could not be excluded, but it could have only weakened the association as it would have gone toward positive association. In the same way, reverse causation bias would have been very unlikely to occur as it would have also gone toward a positive association.

Finally, an indication bias may have occurred if the reason for NSAIDs use (cardiovascular and rheumatologic backgrounds) was associated to prostate cancer. To our knowledge, there is no evidence of such an association in the literature.

Many observational studies investigated the potential protective effect of NSAIDs in cancer and there is striking evidence in colorectal cancer through the diminution of adenomas incidence (preneoplastic state) in group of patients taking NSAIDs, especially anti‐COX‐2 or aspirin [32](#cam41186-bib-0032){ref-type="ref"}, [33](#cam41186-bib-0033){ref-type="ref"}, [34](#cam41186-bib-0034){ref-type="ref"}. In prostate cancer, results were less convincing especially among nonaspirin NSAIDs users. Considering aspirin use, our results were consistent with those of recent meta‐analyses that reported a modest 5--15% reduction in prostate cancer risk associated with aspirin use [12](#cam41186-bib-0012){ref-type="ref"}, [14](#cam41186-bib-0014){ref-type="ref"}, [15](#cam41186-bib-0015){ref-type="ref"}, [16](#cam41186-bib-0016){ref-type="ref"}, [17](#cam41186-bib-0017){ref-type="ref"}. A recent cohort study observed that low dose of aspirin was associated with a decreased risk of prostate cancer (HR 0.64, 95% CI 0.48--0.86) especially after at least 5 years of use (HR 0.42, 95% CI 0.21--0.91) [35](#cam41186-bib-0035){ref-type="ref"}. The Cancer Prevention Study II Nutrition Cohort also showed that daily aspirin use for at least 5 years was associated to a 15% risk reduction of prostate cancer [36](#cam41186-bib-0036){ref-type="ref"}.

Regarding NA‐NSAIDs, results are less convincing in the literature. Our results are consistent with three studies reaching statistical significance with inverse association (OR 0.71, 95% CI 0.58--0.86) [21](#cam41186-bib-0021){ref-type="ref"}, [23](#cam41186-bib-0023){ref-type="ref"}, [24](#cam41186-bib-0024){ref-type="ref"} with neither duration nor frequency‐related trends. A study using the Danish registry nationwide data found a slightly increased prostate cancer risk among NA‐NSAIDs users (OR 1.13, 95% CI 1.10--1.15) [35](#cam41186-bib-0035){ref-type="ref"}, concurring with two Finnish studies, one nationwide [37](#cam41186-bib-0037){ref-type="ref"} and one conducted within the Finnish Prostate Cancer Screening Trial [20](#cam41186-bib-0020){ref-type="ref"}, that found an increased risk of prostate cancer associated with NA‐NSAIDs use, but no apparent trends with either increasing cumulative dose or duration of NA‐NSAIDs use, not supporting causal relationship between NA‐NSAIDs use and prostate cancer risk. All these positive associations could have been due to reverse causation bias and detection bias, exposing to the risk of false‐positive associations. Also, administrative data often lack information about confounding factors and sometimes no latency is taken into account. Due to important heterogeneity in studies, meta‐analysis had failed to show inverse associations of NA‐NSAIDs use on prostate cancer [14](#cam41186-bib-0014){ref-type="ref"}, [15](#cam41186-bib-0015){ref-type="ref"}, [16](#cam41186-bib-0016){ref-type="ref"}, [29](#cam41186-bib-0029){ref-type="ref"}.

Considering grade of cancer, we reported a decreased risk of aggressive prostate cancer occurrence in patients using all type of NSAIDs (high Gleason score, OR 0.62, 95% CI 0.41--0.95 vs. intermediate or low Gleason score, OR 0.82, 95% CI 0.64--1.06). This is in agreement with one study finding significant inverse association of daily aspirin taken in the 12 previous months with highly aggressive tumors with Gleason score ≥7 or Stage III or IV (OR 0.88, 95% CI 0.78--0.99 vs. less aggressive tumors OR 0.94, 95% CI 0.85--1.04) and another showing significant inverse association with all type of NSAID use and tumors with Gleason score ≥7 (OR 0.80, 95% CI 0.64--0.99) versus no association for Gleason score \<7 (OR 0.90, 95% CI 0.77--1.04). The Danish study showed no real trend considering Gleason score [35](#cam41186-bib-0035){ref-type="ref"}. Regarding anti‐COX‐2 activity, no special effect was found in the literature [38](#cam41186-bib-0038){ref-type="ref"}, except one case--control study focusing on coxibs that found a 55% significant decreased risk of prostate cancer, which is consistent with our findings [39](#cam41186-bib-0039){ref-type="ref"}.

Interestingly, the inverse association observed with all‐NSAIDs use was more pronounced in men with a personal history of prostatitis reinforcing the hypothesis that inflammation provides favorable conditions for carcinogenesis [40](#cam41186-bib-0040){ref-type="ref"}, [41](#cam41186-bib-0041){ref-type="ref"}.

In conclusion, our study provides convincing evidence that a frequent and chronic NSAIDs use decreased the risk of prostate cancer, especially aggressive prostate cancer. The specific decreased risk observed among men with a personal history is an additional evidence that targeting chronic inflammation may help preventing prostate carcinogenesis.
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